Ayşe UĞUR, Şükrü Gökhan ELÇİ, Doğangün YÜKSEL

Validation of HPLC method for the determination of chemical and radiochemical purity of a $^{68}Ga-labelled EuK-Sub-kf-(3-iodo-y-) DOTAGA$

The prostate-specific membrane antigen (PSMA) represents an ideal biomarker for molecular imaging. Various PSMAtargeted radioligands are available for prostate cancer imaging. In this study, labeling of PSMA I&T with $^{68}Ga$, as well as validation of the radiochemical purity of the synthesis product by reverse phase radio high-performance liquid chromatography (HPLC) method are intended. Since the standard procedure for the quality control (QC) was not available, definition of chemical and radiochemical purity of $^{68}Ga$-PSMA I&T was carried out according to the Q2 (R1) ICH guideline. The standard QC tests were analyzed with Scintomics 8100 radio-HPLC system equipped with a radioactivity detector. The method was evaluated in terms of linearity, precision and accuracy, LOQ, robustness parameters, and specificity. To assess the radiochemical and chemical purity of $^{68}Ga$-PSMA I&T, the developed method was validated to apply safely to patients. An excellent linearity was found between 1μg/mL and 30 μg/mL, with a limit of detection and limit of quantitation of 0.286 μg/mL and 0.866 μg/mL, respectively for 68Ga-PSMA I&T. The recovery was 96.8 ± 3.8%. The quality control of the final product was performed many times with validated radio-HPLC method and was found to comply with ICH requirements, thus demonstrating the accuracy and robustness of the method for routine clinical practice.

PDF

___

1. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules,European Journal of Nuclear Medicine and Molecular Imaging. 2013; 40: 819-23. doi: 10.1007/s00259-013-2374-2
2. Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42(12): 1974-1800.
3. Chatalic KLS, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JDM, Franssen GM et al. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane, antigen-targeted theranostic agent. Theranostics 2016; 6(6): 849-861. doi: 10.7150/thno.14744
4. Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA Theranostics: Current status and future directions. Molecular Imaging 2018; 17: 1-9. doi: 10.1177/1536012118776068
5. Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P et al. Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Molecular Imaging Biology 2016; 18: 428-436.
6. Elri T, Aras M, Salihoglu YS, Erdemir RU, Cabuk M. A potential pitfall in the use of 68Ga-PSMA PET/CT: Anthracosis. Revista Española de Medicina Nuclear e Imagen Molecular 2017; 36: 65-66.
7. Vamadevan S, Shetty D, Le K, Bui C, Mansberg R et al. Prostate-specific membrane antigen (PSMA) avid pancreatic neuroendocrine tumor. Clinical Nuclear Medicine 2016; 41:804-806.
8. Szydlo M, Pogoda D, Kowalski T, Pocięgiel M, Jadwiński M et al. Synthesis and quality control of 68Ga-PSMA PET/CT tracer used in prostate cancer imaging and comparison with 18F-fluorocholine as a reference point. Journal Pharmacy Science Emergency Drugs 2018; 6: 1.
9. McCarthy M, Langton T, Kumar D, Campbell A. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44(9): 1455-1462.
10. Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A et al. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44(4): 670-677.
11. Bluemel C, Krebs M, Polat B, Linke F, Eiber M et al. 68 Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clinical Nuclear Medicine 2016; 41(7): 515-521.
12. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P et al. 68Ga-PSMA positron emission tomography/ computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Europen Urology 2016; 70: 553-557.
13. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. Journal Nuclear Medicine 2015; 56: 855-861. doi: 10.2967/jnumed.115.156133
14. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2014; 4: 63, 1-15.
15. Schmuck S, Nordlohne S, Klot CA, Henkenberens C, Sohns JM et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44: 960-968. doi: 10.1007/s00259-017- 3669-5
16. Meyer G-J, Mäcke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. European Journal of Nuclear Medicine and Molecular Imaging 2004; 31: 1097-1104. doi: 10.1007/s00259-004-1486-0
17. Eppard E, Homann T, Fuente A de la, Essler M, Rösch F. Optimization of labeling PSMAHBED with ethanol-postprocessed 68Ga and its quality control systems. Journal Nuclear Medicine 2017; 58: 432-437. doi: 10.2967/jnumed.116.177634
18. Taratonenkova NA, Lyamtseva EA, Malysheva AO, Kodina GE. Quality control method for 111In-Oxine radiopharmaceutical composition. Pharmaceutical Chemistry Journal 2019; 52(10): 868-872. doi: 10.1007/s11094-019-1918-6
19. ICH Q2A. 1995; Text on Validation of Analytical Procedures. Geneva Q2A, in 2005 incorporated in Q2(R1).
20. ICH Q2A.1996; Validation of Analytical Procedures: Methodolgy. Geneva Q2B, in 2005 incorporated in Q2(R1).
21. MigliariS, Sammartano A, Scarlattei M, Serreli G. Development and validation of a high-pressure liquid chromatography method for the determination of chemical purity and radiochemical purity of a [68Ga]-labeled Glu-Urea-Lys(Ahx)-HBED-CC (Positron emission tomography) tracer. ACS Omega 2017; 2: 7120-7126.
22. Hubaut M, Fagart A, Tonnelet D. Le Gallium 68. Médecine Nucléaire 2018; 42(6): 463-465.
23. Türkan E. New radiopharmaceuticals and preclinical imaging. Nuclear Medicine Seminars, 2019; 5: 1-9 (in Turkish with an abstract in English).
24. Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA et al. Gallium-68 DOTATATE production with automated pet radiopharmaceutical synthesis system: a three year experience. Asia Ocean Journal Nuclear Medicine Biology 2014; 2(2): 75-86. doi: 10.7508/aojnmb.2017.02.001
25. Velikyan I. 68Ga-based radiopharmaceuticals: production and application relationship. Molecules 2015; 20: 12913-12943.
26. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Research 1994; 54: 1807-1811.
27. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 5981-5986.
28. Olson WC, Heston WDW, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Reviews on Recent Clinical Trials 2007; 2: 182-190.
29. Phani Sekhar Reddy G, Navyasree KS, Jagadish PC, Bhat K. Analytical method development and validation for HPLC-ECD determination of moxifloxacin in marketed formulations. Pharmaceutical Chemistry Journal 2018; 52 (7): 674-679. doi: 10.1007/s11094-018-1879-1